---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-035593"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:39:45.646575+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ChromaDex Q2 net sales up 12% to $22.7M; adjusted EBITDA positive $1.6M

## Summary
- Total net sales $22.7M (+12% YoY); Tru Niagen sales $18.6M (+10% YoY).
- Gross margin 60.2%; operating expenses down $0.7M YoY to $13.9M.
- Net loss approximately breakeven, a $2.2M improvement vs Q2 2023 loss of $2.2M.
- Adjusted EBITDA improved to $1.6M from $0.2M in prior year quarter.
- FDA Orphan Drug and Rare Pediatric Disease Designation for nicotinamide riboside chloride in Ataxia Telangiectasia.

## SEC filing metadata
- accession: 0001628280-24-035593
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828024035593/0001628280-24-035593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828024035593/cdxc-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-035593
- JSON: https://secwatch.observer/filing/0001628280-24-035593.json
- Plain text: https://secwatch.observer/filing/0001628280-24-035593.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.